Name

Denosumab

Alternate Names

Prolia
Xgeva

Abbreviations

None

Category

Ancillary Agent
Biologic therapy (BRM, immunotherapy)

Subcategory

PLEASE SEE IMPORTANT CODING INFORMATION IN REMARKS FIELD
Prevents bone resorption--do not code
RANKL inhibitor

NSC Number

None

Primary Site

Histology

None

Remarks

IMPORTANT CODING NOTE (JULY 12, 2013): This drug was approved by the FDA on June 13, 2013 to treat unresectable giant cell tumors of the bone in both adults and skeletally mature adolescents. If this drug is being prescribed to treat this type of tumor, code as BRM/Immunotherapy. For all other conditions listed in the November release information below, do not code, the drug is considered ancillary.

November 18, 2010: Received FDA approval for the prevention of skeletal-related events in patients with bone metastases from solid tumors.

Coding

Please see remarks for additional information
Glossary